<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20100209003320N21</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2021-07-18</date_registration>
      <primary_sponsor>Tabriz University of Medical Sciences</primary_sponsor>
      <public_title>The effect of propolis supplementation with weight loss diet in treatment  of non-alcoholic fatty liver</public_title>
      <acronym>NAFLD</acronym>
      <scientific_title>The effect of propolis and placebo supplementation with weight loss diet on metabolic status, meta-inflammation, nutritional status and liver function in patients with non-alcoholic fatty liver</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2021-07-23</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>46</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/56177</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Other design features: Individuals in both the placebo and supplement groups will receive a weight loss diet; The amount of calories per person is calculated based on the Mifflin formula and 500 kcal will be deducted from the total calories in order to lose weight. The distribution of macronutrient calories will be 50% carbohydrates, 20% protein and 30% fat, Randomization description: ‏In this study, block randomization will be used to create a balance in the number of samples allocated to each of the study groups (supplement and placebo). All blocks will be the same size, and in this two-group experiment, there will be 6 blocks (including 3 participants in the supplement group and 3 participants in the placebo group). Randomization tool, RAS  (Random allocation software) is version 2.0 that these random software in addition to simple randomization is also able to block randomization. Thus, 46 eligible patients will be blocked based on age, sex and BMI and will be randomly allocated to the supplement group (propolis) or placebo (cornstarch). Allocation concealment is also used for hiding so that the allocated group is not known before the individual is allocated, Blinding description: The person in charge of packaging propolis and placebo supplements without knowing the content will determine the type of supplement or placebo that has no role in the implementation and analysis of the study data. None of the researchers or patients will be aware of the type of combination each person is receiving.</study_design>
      <phase>2-3</phase>
      <hc_freetext>non-alcoholic fatty liver.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: Supplement group (propolis three capsules of 500 mg per day after each meal) for 8 weeks from Shahdineh Company of Isfahan with weight loss diet.The amount of calories for each person will be calculated based on the Mifflin formula and 500 kcal will be deducted from it in order to lose weight. The distribution of macronutrients will be 50% carbohydrates, 20% protein and 30% fat. Intervention 2: Control group: placebo (three capsules of 500 mg of corn starch per day after each meal) for 8 weeks from Shahdineh Company of Isfahan with weight loss diet.The amount of calories for each person will be calculated based on the Mifflin formula and 500 kcal will be deducted from it in order to lose weight. The distribution of macronutrients will be 50% carbohydrates, 20% protein and 30% fat.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
Data collected for the primary outcomes will be shared

When:
Access starting 12 months after publication

To whom:
The data will only be available for people working in academic institutions.

Conditions:
The data of the present study will only be accessible by other researchers , for conducting meta-analysis

Where to obtain:
Ms.Mahlagha, Nikbaf, E-mail address:mahlaghanikbaf@gmail.com , cellphone number: 00989155122119

How to obtain:
The applicant should provide a brief description of the aims and methods of his Meta-analysis . His request will be assessed and , if agreed, the data will be emailed to the applicant. All these procedures will take no longer than 15 days.

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Dr. Mehrangiz Ebrahimimamagani</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Golgasht street ,Attar neyshaburi street, nutriton faculty</address>
        <city>Tabriz</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>5185747731</zip>
        <telephone>+98 41 3334 1113</telephone>
        <email>mebrahimimameghani@gmail.com</email>
        <affiliation>Tabriz University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Dr. Mehrangiz Ebrahimimamagani</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Golgasht street,Attar neyshabori street,Tabriz university of medical science,Nutrition faculty</address>
        <city>Tabriz</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>5185747731</zip>
        <telephone>+98 41 3334 1113</telephone>
        <email>mebrahimimameghani@gmail.com</email>
        <affiliation>Tabriz University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Both sexes
Age 20-50 years
Body mass index (BMI) in the range of 30-40 Kg/m2
Willingness to participate in the study
Non-alcoholic fatty liver disease (NAFLD) (grades 1 and 2)</inclusion_criteria>
      <agemin>20 years</agemin>
      <agemax>50 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>pregnancy, lactation and menopause in women
Skin or gastrointestinal allergies to propolis, honey and any bee  products
Smoking or alcohol use
Following a particular diet in the last three months
Using synthetic or herbal medicines for weight loss in the last three months
Performing weight loss surgery in the past year or strict weight loss diets in the last three  months
Use antibiotics or supplements affecting liver enzyme levels in the last three months
Having symptoms of infectious or inflammatory disease or recent surgery</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>K76.0</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Fatty (change of) liver, not elsewhere classified</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Placebo</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: Supplement group (propolis three capsules of 500 mg per day after each meal) for 8 weeks from Shahdineh Company of Isfahan with weight loss diet.The amount of calories for each person will be calculated based on the Mifflin formula and 500 kcal will be deducted from it in order to lose weight. The distribution of macronutrients will be 50% carbohydrates, 20% protein and 30% fat.</i_keyword>
      <i_keyword>Control group: placebo (three capsules of 500 mg of corn starch per day after each meal) for 8 weeks from Shahdineh Company of Isfahan with weight loss diet.The amount of calories for each person will be calculated based on the Mifflin formula and 500 kcal will be deducted from it in order to lose weight. The distribution of macronutrients will be 50% carbohydrates, 20% protein and 30% fat.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Tumor necrosis factor. Timepoint: At the beginning and 8 weeks after the start of the study. Method of measurement: ELISA method.</prim_outcome>
      <prim_outcome>MCP-1. Timepoint: At the beginning and 8 weeks after the start of the study. Method of measurement: ELISA method.</prim_outcome>
      <prim_outcome>Toll-like receptor 4. Timepoint: At the beginning and 8 weeks after the start of the study. Method of measurement: ELISA method.</prim_outcome>
      <prim_outcome>Fasting Blood Sugar. Timepoint: At the beginning and 8 weeks after the start of the study. Method of measurement: Enzymatic method.</prim_outcome>
      <prim_outcome>Insulin. Timepoint: At the beginning and 8 weeks after the start of the study. Method of measurement: ELISA method.</prim_outcome>
      <prim_outcome>Total cholesterol. Timepoint: At the beginning and 8 weeks after the start of the study. Method of measurement: Enzymatic method.</prim_outcome>
      <prim_outcome>Triglyceride. Timepoint: At the beginning and 8 weeks after the start of the study. Method of measurement: Enzymatic method.</prim_outcome>
      <prim_outcome>HDL-C. Timepoint: At the beginning and 8 weeks after the start of the study. Method of measurement: enzymatic colorimetric method using spectrophotometer.</prim_outcome>
      <prim_outcome>HOMA-IR. Timepoint: At the beginning and 8 weeks after the start of the study. Method of measurement: According to the formula.</prim_outcome>
      <prim_outcome>Body mass index. Timepoint: At the beginning and 8 weeks after the start of the study. Method of measurement: According to the formula.</prim_outcome>
      <prim_outcome>Waist circumference. Timepoint: At the beginning and 8 weeks after the start of the study. Method of measurement: Meter.</prim_outcome>
      <prim_outcome>Waist-to-hip ratio (WHR). Timepoint: At the beginning and 8 weeks after the start of the study. Method of measurement: According to the formula.</prim_outcome>
      <prim_outcome>Waist to Height Ratio (WHtR). Timepoint: At the beginning and 8 weeks after the start of the study. Method of measurement: According to the formula.</prim_outcome>
      <prim_outcome>Alanine aminotransferase. Timepoint: At the beginning and 8 weeks after the start of the study. Method of measurement: enzymatic method.</prim_outcome>
      <prim_outcome>Aspartate aminotransferase. Timepoint: At the beginning and 8 weeks after the start of the study. Method of measurement: Enzymatic method.</prim_outcome>
      <prim_outcome>Gamma Glutamyl transferase. Timepoint: At the beginning and 8 weeks after the start of the study. Method of measurement: Enzymatic method.</prim_outcome>
      <prim_outcome>Fatty liver grade. Timepoint: At the beginning and 8 weeks after the start of the study. Method of measurement: Ultrasound findings.</prim_outcome>
      <prim_outcome>NAFLD fibrosis score. Timepoint: At the beginning and 8 weeks after the start of the study. Method of measurement: According to the formula.</prim_outcome>
      <prim_outcome>Energy and macronutrients  received. Timepoint: At the beginning and 8 weeks after the start of the study. Method of measurement: 3-Day Food Record form.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Tabriz University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2021-02-16</approval_date>
        <contact_name>Ethics committee of Tabriz university of medical sciences</contact_name>
        <contact_address>Tabriz University of Medical Sciences, Attar Neishabouri Ave, Golgasht St Tabriz East Azarbaijan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
